Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

The deaths of two women in Georgia have been tied to a state law that bans most abortions after roughly six weeks.

Report on how AI is redefining market landscape- The global powered air purifying respirator market size is estimated to grow ...

A summer wave of cases locally and across the country may be on the decline and a vaccine targeting the latest variants is ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in ...

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.Phase 3 study for ...

Health insurers offering Affordable Care Act marketplace plans are proposing a median premium increase of 7% for 2025. These ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...